Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies

被引:0
|
作者
Brijker, F
Magee, CC
Tervaert, JWC
O'Neill, S
Walshe, JJ
机构
[1] Beaumont Hosp, Dept Resp Med, Dublin 2, Ireland
[2] Univ Groningen Hosp, Dept Clin Immunol, NL-9713 EZ Groningen, Netherlands
关键词
ANCA; vasculitis; Wegener's granulomatosis; microscopic polyangiitis;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Objective scoring systems of disease activity and disease-associated damage have proven useful in the management of patients with systemic vasculitis. Patients and methods: We used the recently designed Birmingham vasculitis activity score (BVAS; maximum score 63) and vasculitis damage index (VDI; maximum score 59) to assess initial activity and long-term damage, respectively, in ANCA positive patients from one center over a 3-year period. Thirty-two patients with ANCA vasculitis were identified and analyzed as an historic cohort. The median BVAS for all vasculitis patients at first presentation was 19 (range 6 - 36). Patients with Wegener's granulomatosis had a significantly higher total score and respiratory BVAS score compared to the 15 with microscopic polyangiitis. The majority of patients received standard cyclophosphamide/steroid treatment. Results: At the end of follow-up (mean 24.9 months), 4 patients had died; all patients had evidence of permanent organ damage. The median total VDI score at last follow-up was 4.0 (range 0 - 11), with no differences between patients with Wegener's granulomatosis and microscopic polyangiitis. The VDI was not associated with the number of relapses. A high initial BVAS was found to correlate with a later high vasculitis damage index (r = 0.56). Initial renal or respiratory involvement was also associated with longterm damage in the same organ system. Conclusion: Although mortality from ANCA-associated vasculitis has decreased, morbidity remains a common problem. High early-disease activity may identify patients at high risk of long-term organ damage, allowing more effective individualized therapy. This hypothesis requires validation in a prospective, controlled study.
引用
收藏
页码:344 / 351
页数:8
相关论文
共 50 条
  • [41] Endobronchial Ulceration: A Different Manifestation of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
    Gonsalves, Ana Sara
    Freitas, Filipa Menezes
    Sousa, Claudia
    Carvalho, Joao
    Teixeira, Vitor
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [42] Vasculitis management: discovery of antineutrophil cytoplasmic antibodies (ANCA)
    Guillevin, Loic
    PRESSE MEDICALE, 2007, 36 (05): : 843 - 844
  • [43] Antineutrophil cytoplasmic antibodies (ANCA). Their contribution to the pathogenesis of vasculitis
    Mirapeix, E
    MEDICINA CLINICA, 1998, 110 (20): : 778 - 780
  • [44] ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES - DIAGNOSTIC USE IN VASCULITIS AND GLOMERULONEPHRITIS
    BOSCH, X
    MIRAPEIX, E
    FONT, J
    LOPEZSOTO, A
    RODRIGUEZ, R
    VIVANCOS, J
    REVERT, L
    INGELMO, M
    URBANOMARQUEZ, A
    MEDICINA CLINICA, 1994, 102 (11): : 412 - 417
  • [45] Antineutrophil cytoplasmic antibodies (ANCA) and small vessel vasculitis
    Mareen, P
    De Walle, SV
    Bernaert, P
    Vanhouteghem, H
    Dierick, J
    ACTA CLINICA BELGICA, 2003, 58 (03) : 193 - 200
  • [46] Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis A Series of 49 Patients and Review of the Literature
    Comarmond, Cloe
    Crestani, Bruno
    Tazi, Abdellatif
    Hervier, Baptiste
    Adam-Marchand, Sylvain
    Nunes, Hilario
    Cohen-Aubart, Fleur
    Wislez, Marie
    Cadranel, Jacques
    Housset, Bruno
    Lloret-Linares, Celia
    Seve, Pascal
    Pagnoux, Christian
    Abad, Sebastien
    Camuset, Juliette
    Bienvenu, Boris
    Duruisseaux, Michael
    Hachulla, Eric
    Arlet, Jean-Benoit
    Hamidou, Mohammed
    Mahr, Alfred
    Resche-Rigon, Matthieu
    Brun, Anne-Laure
    Grenier, Philippe
    Cacoub, Patrice
    Saadoun, David
    MEDICINE, 2014, 93 (24) : 340 - 349
  • [47] ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS IN
    Popescu, M. L.
    Predeteanu, D.
    Opris-Belinski, D.
    Balanescu, A.
    Berghea, F.
    Borangiu, A.
    Constantinescu, C.
    Groseanu, L.
    Ionescu, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (01) : S27 - S28
  • [48] Antineutrophil cytoplasmic antibody-associated vasculitis
    Konda, Raghunandan
    Rajasekaran, Arun
    Rizk, Dana V.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2024, 33 (05): : 503 - 511
  • [49] Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Berti, Alvise
    Warner, Roscoe
    Johnson, Kent
    Cornec, Divi
    Schroeder, Darrell
    Kabat, Brian
    Langford, Carol A.
    Hoffman, Gary S.
    Fervenza, Fernanado C.
    Kallenberg, Cees G. M.
    Seo, Philip
    Spiera, Robert
    St Clair, E. William
    Brunetta, Paul
    Stone, John H.
    Merkel, Peter A.
    Specks, Ulrich
    Monach, Paul A.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (07) : 1114 - 1121
  • [50] Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement
    Rihova, Z
    Jancova, E
    Merta, M
    Rysava, R
    Reiterova, J
    Zabka, J
    Tesar, V
    KIDNEY & BLOOD PRESSURE RESEARCH, 2005, 28 (03): : 144 - 152